Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 3.64M P/E - EPS this Y 98.00% Ern Qtrly Grth -
Income -17.91M Forward P/E -1.66 EPS next Y 70.90% 50D Avg Chg -32.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -76.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -94.00%
Recommedations 2.00 Quick Ratio 0.96 Shares Outstanding 17.27M 52W Low Chg 4.00%
Insider Own 0.04% ROA -207.95% Shares Float 17.26M Beta 0.47
Inst Own 11.46% ROE -1,048.70% Shares Shorted/Prior 0.90M/175.77K Price 2.02
Gross Margin - Profit Margin - Avg. Volume 274,620 Target Price -
Oper. Margin - Earnings Date - Volume 65,494 Change -3.81%
About TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.

TransCode Therapeutics, Inc. News
12/18/24 TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial
11/29/24 TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
11/28/24 Transcode Therapeutics issues 21.2M shares at 37.7c in private placement
11/27/24 TransCode Therapeutics, Inc. Announces $8 Million Private Placement
07:05 AM Transcode Therapeutics announces 1-for-33 reverse stock split
11/12/24 TransCode Therapeutics Open Letter to Shareholders
11/05/24 TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
10/23/24 TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
10/10/24 TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology
09/17/24 TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate
09/10/24 TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
09/05/24 TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
08/15/24 TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
07/24/24 TransCode Therapeutics, Inc. Announces Closing of Public Offering
07/22/24 TransCode Therapeutics, Inc. Announces Pricing of Public Offering
07/22/24 TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
06/10/24 Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements
05/29/24 TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
04/15/24 TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
04/03/24 TransCode Therapeutics Reports 2023 Results; Provides Business Update
RNAZ Chatroom

User Image Yio123 Posted - 12 minutes from now

$RNAZ ON THIS NEWS THIS PLUM NOW TIME TO GAP UP TO $6 BUT B4 THAT WE WILL SEE 1.39$

User Image Vedran1 Posted - 1 day ago

$RNAZ I think someone tried to spark a pump last PM. Did not work.

User Image Vedran1 Posted - 1 day ago

$RNAZ I feel more and more as a rower of a sinking galley. Or a robbed investor.

User Image StockRedBaron Posted - 1 day ago

$RNAZ OK RNAZ, time for your MONKEY MOVE!!!

User Image Cinderblocks Posted - 1 day ago

$RNAZ Bid ask spread is wide. It just takes some buying pressure. 🤞

User Image phantomtrader75 Posted - 1 day ago

$RNAZ TOXIC

User Image Cinderblocks Posted - 1 day ago

$RNAZ Low floaters have been on fire lately. This one has about 600-700k shares outstanding. Was pushed up last night on basically no volume. Imagine what some serious volume can do. Risky play so don't invest too much.

User Image skidog47 Posted - 1 day ago

$RNAZ just entered.

User Image Majid74 Posted - 1 day ago

$RNAZ wtf?

User Image phantomtrader75 Posted - 1 day ago

$RNAZ omg

User Image AZOZ Posted - 2 days ago

$RNAZ oversold swing idea 💡

User Image Majid74 Posted - 2 days ago

$RNAZ why no move?

User Image 50shadesoftrades Posted - 2 days ago

$RNAZ added

User Image phantomtrader75 Posted - 2 days ago

$RNAZ epic squeeze coming. It literally took that three minutes to go up 60%. Sign of things to come.

User Image StockRedBaron Posted - 2 days ago

$RNAZ Did you all see that CRAZY action??? MAN!!! This may continue tomorrow...WOOOOOO!

User Image Majid74 Posted - 2 days ago

$RNAZ let's go reversal play PT 20$🚀🚀🚀

User Image Cinderblocks Posted - 2 days ago

$RNAZ Some interesting action tonight. Managed to sell half my position at 5.20. Let's see what tomorrow brings.

User Image phantomtrader75 Posted - 2 days ago

$RNAZ SQUEEZE

User Image nostic Posted - 2 days ago

$RNAZ there’s some YouTube videos out there with various “people from the field” talking about how promising mRNA treatments would be if we could just get them past the liver. Zero mention of Transcode. It’s unreal. What this company is doing is huge, and even people in the industry have no clue.

User Image phantomtrader75 Posted - 2 days ago

$RNAZ this feels malicious and intentional.

User Image Cinderblocks Posted - 2 days ago

$RNAZ Looks interesting today. Like it's going to have a little run. 👀

User Image gunners95 Posted - 3 days ago

$RNAZ another reverse stock split soon 😂

User Image gscdefense Posted - 3 days ago

$RNAZ surprised at such low levels of shorts available

User Image rock_it_stocks Posted - 4 days ago

$RNAZ Your conclusions are uneducated and uninformed. You can do better, for miR-10b is one of the most extensively studied miRNAs out there. Actually, preliminary results are consistent with preclinical and FIH studies. A 66% reduction of miR-10b in humans 24 hours after an initial infusion of a 1/8th strength dosage is groundbreaking news. MN-anti-miR10b (TTX-MC138) persistently inhibits the expression of miR-10b, decreasing it by 90% within 48 hours, and a 99% downregulation is observed after two weekly treatments. TTX-MC138 has been proven effective in metastases regression without recurrence in study after study by those with a mental capacity far superior than some rando stocktwit troll, but thanks for letting us know your opinion!

User Image Vedran1 Posted - 4 days ago

$RNAZ Reading PRE 14A from Dec 19 The Board is recomending to vote "FOR" proposals - as Transcode has an obligation to ask us for approval of certain the private placement terms - as per the Transcode's Nov 29 security purchase agreement with "certain accredited investors". Also, considering significant DILUTION that might happen after issuance of shares upon exercise of warrants, Transcode is asking us for the approval of the same agreement terms - as required by NASDAQa rules regarding dilution possibilities. Finally, reading in between lines: "Effect on Current Stockholders if the Issuance Proposal is Not Approved" and "Risk of Approval of the Issuance Proposal" I have reached conclusion The Board is telling us to vote "NO" to the proposals. If true, this is a brilliant move and likely good news are in making within next few months or shortlyy after the meeting.

User Image TMMC Posted - 4 days ago

$RNAZ Horrible results,just 66% efficiency..better luck next time

User Image phantomtrader75 Posted - 5 days ago

$RUM $RNAZ come on over and run baby run

User Image rock_it_stocks Posted - 5 days ago

$RNAZ I don't see anything that is new or has changed from the 8-K to the S-1 to the Pre-14A. Might I suggest voting "Against" the two proposals?

User Image BabyDoll1 Posted - 6 days ago

$RNAZ Wow.. horrible

User Image GaryBx105 Posted - 6 days ago

$RNAZ Huge dilution from cashless D warrant exercise takes loan sharking to a new level.

Analyst Ratings
HC Wainwright & Co. Buy Sep 6, 24
HC Wainwright & Co. Buy Aug 15, 24
HC Wainwright & Co. Buy May 29, 24
HC Wainwright & Co. Buy May 16, 24
HC Wainwright & Co. Buy Apr 16, 24
HC Wainwright & Co. Buy Apr 3, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Fitzgerald Thomas A Chief Financial Offi.. Chief Financial Officer Sep 28 Buy 0.51 49,350 25,168 56,318 10/02/23
Dudley Robert Michael Chief Executive Offi.. Chief Executive Officer Sep 28 Buy 0.51 98,000 49,980 180,262 10/02/23
Dudley Robert Michael Chief Executive Offi.. Chief Executive Officer Jun 20 Buy 2.6 18,607 48,378 82,262 06/22/23
Dudley Robert Michael Chief Executive Offi.. Chief Executive Officer Jun 09 Buy 2.76 19,000 52,440 912,114 06/13/23
Dudley Robert Michael Chief Executive Offi.. Chief Executive Officer Sep 14 Buy 1.15 20,000 23,000 893,114 09/16/22